Floatz logo

Ap-Pa02

Lung Infection Pseudomonal

Armata Pharmaceuticals, Inc.Phase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Lung Infection Pseudomonal cohort.

Asset / SponsorPhaseRating
POLY(ACETYL, ARGINYL)GLUCOSAMINE (25000-50000 MW)
Synspira, Inc.
Phase 1CC
Aztreonam Lysine
Gilead Sciences
Phase 3NR
Aztreonam Lysine
Gilead Sciences
Phase 3NR

Same molecule, other indications

Ap-Pa02 is also rated in:

Pseudomonas aeruginosa infectious diseaseDormant
BB
Indicative ·
69 / 100
View asset →
pneumoniaDormant
BB
Indicative ·
69 / 100
View asset →
bronchiectasisDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →